Find A Study Site
Join A Clinical Trial For A New UTI Vaccine
For Females Aged 18-64 Years Who Experience UTI Linked to E. coli
The study is investigating a new vaccine designed to prevent urinary tract infections (UTIs) caused by E. coli, a bacteria commonly responsible for these infections. The trial will evaluate the vaccine’s efficacy and safety by comparing the health outcomes (including rates of UTIs and side effects) over one year between participants who receive the new vaccine and those who do not receive any form of vaccination.
More information about the study can be found on the study page.
If you believe you meet the eligibility criteria for this study outlined on the study page, follow the instructions below to locate and contact the nearest clinical trial site.
This study is currently enrolling participants in the United States, Argentina, Belgium, South Africa and Spain.
Step 1: Locate Your Nearest Study Site
Use the lists and maps below to find the study site closest to you. The study sites are listed by country.
United States
NEW JERSEY – Secaucus
Site Name: Riverside Medical Group
Contact Name: Luz Taborda
Phone Number: (+1) 551-255-3859
Email: [email protected]
PUERTO RICO – San Juan
Site Name: GCM Medical Group
Contact Name: Azaria Candelario
Phone Number: (+1) 787-936-2100 ext.107
Email: [email protected]
WASHINGTON – Seattle
Site Name: Seattle Clinical Research Center
Contact Name: Breana Barnes
Phone Number: (+1) 206-522-3330
Email: [email protected]
WASHINGTON – Wenatchee
Site Name: Confluence Health
Contact Name: Claire Goveia
Phone Number: (+1) 509-436-4050 ext. 66792
Email: [email protected]
Argentina
CIUDAD AUTÓNOMA BUENOS AIRES
Site Name: Clinical Trials Division Stamboulian
Contact Name: Pablo Luchetti
Phone Number: (+54) 91165369121
Email: [email protected]
Belgium
ANZEGEM
Site Name: Praktijk Bouvelo
Contact Name: Klaas Vercruysse
Phone Number: (+32) 496376259
Email: [email protected]
BRUSSELS
Site Name: European Plotkin Institute for Vaccines
Contact Name: Odette Mukangenzi
Phone Number: (+32) 25558070
Email: [email protected]
IEPER
Site Name: Jan Yperman Ziekenhuis
Contact Name: Florence Havegheer
Phone Number: (+32) 57357297
Email: [email protected]
KLUISBERGEN
Site Name: Kormont BV
Contact Name: Klaas Vercruysse
Phone Number: (+32) 496376259
Email: [email protected]
MECHELEN
Site Name: AZ Sint Maarten
Contact Name: Valerie Vanzulpele
Phone Number: (+32) 15891667
Email: [email protected]
South Africa
BOKSBURG
Site Name: Reimed PTY LTD
Contact Name: Shandre Phillips
Phone Number: (+27) 672482255
Email: [email protected]
DURBAN
Site Name: Enhancing Care Foundation
Contact Name: Penelope Madlala
Phone Number: (+27) 0649757205
Email: [email protected]
JOHANNESBURG
Site Name: Newtown Clinical Research Centre
Contact Name: Thobeka Zuma
Phone Number: (+27) 114920336
Email: [email protected]
Spain
BARCELONA
Site Name: Hospital del Mar
Contact Name: María Fernández
Phone Number: (+34) 932483251
Email: [email protected]
MADRID
Site Name: Hospital Universitario La Paz
Contact Name: Carlos Oñoro
Phone Number: (+34) 912071876
Email: [email protected]
MADRID
Site Name: Hospital Universitario Puerta de Hierro
Contact Name: Paloma Rodríguez
Phone Number: (+34) 911916480
Email: [email protected]
MADRID
Site Name: Hospital Universitario 12 de Octubre
Contact Name: José Medina Polo
Phone Number: (+34) 913908121
Email: [email protected]
Step 2: Contact the Study Site
Once you have identified the nearest study site, reach out to them via email or phone to express your interest in participating. If you are unsure whether you meet the study eligibility criteria or have any specific questions about the trial, feel free to ask when you reach out to the study site. You can use the template below:
Subject: Interest in UTI Vaccine Clinical Trial Participation
Dear [Research Site Contact],
I am interested in participating in the clinical trial for a new UTI vaccine for females aged 18-64 who experience UTIs linked to E. coli. I would like to learn more about the next steps for enrollment.
Please let me know how I can proceed and if any further information is required.
Thank you for your time.
Best regards,
[Your Name]
[Your Contact Information]
